Related Experiment Video
Updated: Jul 4, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
Published on: February 15, 2022
[Biological treatment options for Graves' ophthalmopathy]
Daniel El Fassi1, Claus Henrik Nielsen, Laszlo Hegedüs
1Odense Universitetshospital, Endokrinologisk Afdeling M. fassi@dadlnet.dk
Abstract:
The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Graves' Disease I: Introduction
Graves Disease II: Pathophysiology
Angle Closure Glaucoma: Treatment
Ophthalmic Drug Delivery Systems
Glaucoma: Overview